Chimeric receptors with antibody binding ability

By using the chimeric receptor CARFcR to achieve the multi-targeting capability of CAR-T cells, the problem of poor ADCC efficacy in CAR-T cell therapy has been solved, enhancing the killing power against a variety of tumor cells and making it suitable for the treatment of heterogeneous tumors.

CN122421985APending Publication Date: 2026-07-17NATIONAL UNIVERSITY OF SINGAPORE
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
NATIONAL UNIVERSITY OF SINGAPORE
Filing Date
2024-11-20
Publication Date
2026-07-17

Smart Images

  • Figure CN122421985A_ABST
    Figure CN122421985A_ABST
Patent Text Reader

Abstract

本文描述了允许经由两种主要机制连接癌细胞中表达的多个靶标的受体配置：经由抗体衍生的单链可变片段(scFv)直接结合，以及通过抗体的Fc组分的高亲和力接合间接结合。当在人T淋巴细胞中表达时，这些受体(CARFcR)可以同时或依次触发强大的CAR‑T细胞活性以及抗体依赖性细胞毒性(ADCC)。CARFcR T细胞不受可溶性抗体的影响，但它们可以被与靶细胞结合的抗体重定向和活化。因此，此类T细胞可用于使用临床上可用的抗体“即时”将过继性T细胞疗法重定向至另一种肿瘤相关抗原。它们还提供了一种用单一受体同时靶向多个抗原的实用方法，这一特征在针对表型异质性肿瘤的细胞疗法中应该有用。
Need to check novelty before this filing date? Find Prior Art